Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Candesartan for Migraine Prophylaxies. The Lancet 2025 . Discussion by:

Guest:
Max Schidt, MD
Resident - Family Medicine Residency Program
Jefferson Health - Abington

2. One vs two dose HPV vaccination for prevention of HPV infection – The New England Journal of Medicine 2025. Discussion by:

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

3. The Surpass CVOT trial for prevention of MACE in people with Diabetes – The New England Journal of Medicine 2025. Discussion by:

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

4. The New American Cancer Society Guidelines for Screening for cervical cancer – that includes self swab for HPV. Discussion by:

Guest:
Amy Clouse, MD
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.

This Podcast Episode does not offer CME/CE Credit.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/responding-to-the-science-biologics-in-practice-in-copd-10511

Summary
This enduring podcast activity provides pulmonologists and clinicians managing COPD with timely updates on the evolving role of biologics management. Featuring expert discussions, the program explores recent GOLD guideline revisions, the integration of new and emerging biologic therapies, and evidence-based decision-making based on clinical trial data and real-world practice.

Covering guidelines, clinical trials, and clinical scenario, this activity emphasizes the translation of complex data into practical strategies. Learners will gain improved knowledge and competence related to patient selection, eosinophil thresholds, and clinical decision making.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives

• Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD, including patient populations and outcomes
• Integrate the use of biologic agents into the management of patients with COPD based on guidelines and clinical evidence for new and emerging agents

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an independent medical education grant from GSK and an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/adhd-sleep-and-symptom-control-10355

Summary
Early-morning symptom control remains a critical gap in ADHD management, often contributing to family stress and impaired daily functioning. In this podcast/webcast activity, Dr. Joel Young and Jo Hughes, DMSc, PA-C, CAQ-PSY, explore the limitations of traditional ADHD medications in achieving full-day coverage and discuss available strategies to improve early-morning outcomes. Learners will gain practical insights into the clinical use of nighttime-dosed medications, including an innovative delayed-release/extended-release stimulant, and understand the pharmacologic characteristics that contribute to its efficacy in providing sustained symptom control.

This podcast was recorded and is being used with permission of the presenters.

Learning Objective

• Examine the ADHD treatment options that use nighttime dosing to achieve full-day symptom control

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.50 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from Collegium Pharmaceutical, Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:

https://www.mycme.com/courses/personalized-antidepressant-choices-for-better-outcomes-in-mdd-10266

Summary
Emphasizing a measurement-based, patient-centered model, this is an enduring podcast/webcast designed for psychiatrists who seek to refine their approach to managing major depressive disorder (MDD). Despite an expanding array of pharmacologic options, many patients continue to experience side effects and residual symptoms that undermine adherence and long-term recovery. Led by Drs. Gregory Mattingly and Gerald Maguire, this activity equips clinicians with evidence-based strategies to compare the nuanced risk–benefit profiles of antidepressants and apply them to individualized treatment plans.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives

• Assess the risk–benefit profiles of available antidepressants, including their impact on residual symptoms, to optimize treatment decisions for patients with MDD
• Implement personalized, measurement-based treatment strategies for patients with MDD to address residual symptoms, promote adherence, and improve outcomes

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. FDA change in Boxed Warning Label for Hormone Replacement Therapy. Discussion by:

Guest:
Anupriya Grover Wenk, DO
Faculty - Family Medicine Residency Program
Jefferson Health - Abington

2. Evolocumab in Patients without a Previous Myocardial Infarction or Stroke – The New England Journal of Medicine 2025. Discussion by:

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

3. AI-Powered Lifestyle Intervention vs Human Coaching in the Diabetes Prevention Program – JAMA. Discussion by:

Guest:
Neil Skolnik, MD
Professor of Family and Community Medicine
Sidney Kimmel Medical College Thomas Jefferson University
Associate Director - Family Medicine Residency Program
Jefferson Health – Abington

4. Incremental effect of healthy lifestyle habits when taking GLP-1 RA medications on Cardiac Risk Reduction. Discussion by:

Guest:
Joe Gonella, MD
Resident– Family Medicine Residency Program
Jefferson Health – Abington

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.

This Podcast Episode does not offer CME/CE Credit.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.